Multiple myeloma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Novartis, AbbVie, Pfizer, Alliance Foundation Trials, LLC, Celgene

The Multiple myeloma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Multiple myeloma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple myeloma Market.

Some of the key takeaways from the Multiple myeloma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Multiple myeloma treatment therapies with a considerable amount of success over the years. 
• Multiple myeloma companies working in the treatment market are Poseida Therapeutics, Ionis Pharmaceuticals, CASI Pharmaceuticals, Sorrento Therapeutics, Cartesian Therapeutics, Rapa Therapeutics, Novartis, AbbVie, Pfizer, Alliance Foundation Trials, LLC., Karyopharm Therapeutics Inc., Cartesian Therapeutics, Celgene, iTeos Belgium SA, Pfizer, and others, are developing therapies for the Multiple myeloma treatment 

• Emerging Multiple myeloma therapies in the different phases of clinical trials are- P-BCMACD19- ALLO1, ION251, CID-103, STI-1492, Descartes 08, RAPA-201, PHE885, Venetoclax, Elranatamab, Lenalidomide, Selinexor, Descartes-25, Lenalomide, EOS884448, Elranatamab + Nirogacestat, and others are expected to have a significant impact on the Multiple myeloma market in the coming years.   
• In February 2023, the European Medicines Agency (EMA) announced the acceptance of elranatamab’s marketingauthorization application (MAA). Pfizer also announced that the US Food and Drug Administration (FDA) had grantedPriority Review for the company’s Biologics License Application (BLA) for elranatamab for the treatment of patients withrelapsed or refractory multiple myeloma (RRMM).
• In November 2022, Pfizer announced that elranatamab had been granted Breakthrough Therapy Designationby theFDA. In addition, elranatamab has been granted Orphan Drug Designation by the FDA and the EMA for the treatment ofMM.
• In March 2022, Pfizer initiated a randomized, 2-arm, Phase III study of Elranatamab (PF-06863135) versus Lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positiveafter undergoing autologous stem-cell transplantation.
• In February 2021, Pfizer initiated an open-label, multicenter, non-randomized Phase II study ofelranatamab monotherapy in people with multiple myeloma who are refractory to at least one proteasome inhibitor,one immunomodulatory drug, and one anti-CD38 monoclonal antibody.

Multiple myeloma Overview

A clonal plasma cell proliferative condition called multiple myeloma (MM) is characterised by an aberrant rise in monoclonal immunoglobulin levels. If left unchecked, the excessive creation of these plasma cells can eventually result in injury to a particular end organ.

Get a Free Sample PDF Report to know more about Multiple myeloma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight

Emerging Multiple myeloma Drugs Under Different Phases of Clinical Development Include:

• P-BCMACD19- ALLO1: Poseida Therapeutics
• ION251: Ionis Pharmaceuticals
• CID-103: CASI Pharmaceuticals
• STI-1492: Sorrento Therapeutics
• Descartes 08: Cartesian Therapeutics
• RAPA-201: Rapa Therapeutics
• PHE885: Novartis
• Venetoclax: AbbVie
• Felzartamab: Janssen Pharmaceutical
• Elranatamab: Pfizer
• Lenalidomide: Alliance Foundation Trials, LLC.
• Selinexor: Karyopharm Therapeutics Inc
• Descartes-25: Cartesian Therapeutics
• Lenalomide: Celgene
• EOS884448: iTeos Belgium SA
• Elranatamab + Nirogacestat: Pfizer

Route of Administration

Multiple myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Multiple myeloma Pipeline Therapeutics Assessment

• Multiple myeloma Assessment by Product Type
• Multiple myeloma By Stage and Product Type
• Multiple myeloma Assessment by Route of Administration
• Multiple myeloma By Stage and Route of Administration
• Multiple myeloma Assessment by Molecule Type
• Multiple myeloma by Stage and Molecule Type

DelveInsight’s Multiple myeloma Report covers around 130+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Multiple myeloma product details are provided in the report. Download the Multiple myeloma pipeline report to learn more about the emerging Multiple myeloma therapies

Some of the key companies in the Multiple myeloma Therapeutics Market include:

Key companies developing therapies for Multiple myeloma are – GlaxoSmithKline, Bristol-Myers Squibb, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca, Takeda, Novartis, Teva Pharma, Amgen, ONO Pharma, Genetech, Celegene Corp., Abbvie, Sanofi, Karyopharm, and others.

Multiple myeloma Pipeline Analysis:

The Multiple myeloma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Multiple myeloma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple myeloma Treatment.
• Multiple myeloma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Multiple myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple myeloma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Multiple myeloma drugs and therapies

Multiple myeloma Pipeline Market Drivers

• Rising prevalence of multiple myeloma worldwide, increasing investment for healthcare infrastructure are some of the important factors that are fueling the Multiple myeloma Market.

Multiple myeloma Pipeline Market Barriers

• However, high cost associated with the treatment of multiple myeloma, lack of healthcare infrastructure in developing economies and other factors are creating obstacles in the Multiple myeloma Market growth.

Scope of Multiple myeloma Pipeline Drug Insight    

• Coverage: Global
• Key Multiple myeloma Companies: Poseida Therapeutics, Ionis Pharmaceuticals, CASI Pharmaceuticals, Sorrento Therapeutics, Cartesian Therapeutics, Rapa Therapeutics, Novartis, AbbVie, Pfizer, Alliance Foundation Trials, LLC., Karyopharm Therapeutics Inc., Cartesian Therapeutics, Celgene, iTeos Belgium SA, Pfizer, and others
• Key Multiple myeloma Therapies: P-BCMACD19- ALLO1, ION251, CID-103, STI-1492, Descartes 08, RAPA-201, PHE885, Venetoclax, Elranatamab, Lenalidomide, Selinexor, Descartes-25, Lenalomide, EOS884448, Elranatamab + Nirogacestat, and others
• Multiple myeloma Therapeutic Assessment: Multiple myeloma current marketed and Multiple myeloma emerging therapies
• Multiple myeloma Market Dynamics: Multiple myeloma market drivers and Multiple myeloma market barriers 

Request for Sample PDF Report for Multiple myeloma Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services